Report 4-week efficacy data for Ampreloxetine Phase 3 registrational program
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 30 Sep 2021
- Delivered
- September 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Phase 3 registrational program ongoing; 4 - week efficacy data expected Q3 2021”
What we found
Evidence strength A What the grades mean
The company reported the four-week efficacy data for the SEQUOIA Phase 3 study in September 2021, which was within the Q3 2021 deadline, although the study did not meet its primary endpoint.
-
A Theravance Biopharma, Inc. 10-K filed 2022-02-28
“In September 2021, we reported that the four-week SEQUOIA Phase 3 clinical study did not meet its primary endpoint.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Ampreloxetine Phase 3 efficacy data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Theravance Biopharma, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C583107-021437 · Corrections policy